<Summary id="CDR0000790384" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Treatment for children with salivary gland tumors is surgical removal whenever possible, with additional use of radiation therapy in certain cases. Get detailed information about the treatment of childhood salivary gland tumors this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">Childhood Salivary Gland Tumors (PDQ®): Treatment</SummaryURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038946">salivary gland cancer</TermRef></MainTopics><SummaryAbstract><Para id="_1556">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood salivary gland tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_1557">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>childhood salivary gland tumors</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Salivary Gland Tumors Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Salivary Gland Tumors Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Salivary Gland Tumors Treatment</AltTitle><SummarySection id="_1979"><Title>Salivary Gland Tumors</Title><SummarySection id="_934"><Title>Incidence</Title><Para id="_935">Salivary gland tumors are rare and account for 0.5% of all malignancies in children and adolescents. After rhabdomyosarcoma, they are the most common tumor in the head and neck.<Reference refidx="1"/><Reference refidx="2"/> Salivary gland tumors may occur after radiation therapy and chemotherapy are
given for the treatment of primary leukemia or solid tumors.<Reference refidx="3"/><Reference refidx="4"/></Para></SummarySection><SummarySection id="_1484"><Title>Clinical Presentation</Title><Para id="_1485">Most  salivary gland neoplasms arise in the parotid gland.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/> About 15% of
these tumors arise in the submandibular glands or in the minor salivary
glands under the tongue and jaw.<Reference refidx="8"/>  These tumors are most frequently benign but
 may be malignant, especially in young children.<Reference refidx="11"/> In a systematic review of pediatric salivary gland tumors, the median age of patients was 13.3 years, and most tumors occurred in the second decade of life. There is a slight female predominance.<Reference refidx="12"/></Para></SummarySection><SummarySection id="_936"><Title>Histology and Molecular Features</Title><Para id="_937">The most common malignant salivary gland tumor in children
 is mucoepidermoid carcinoma, followed by acinic cell carcinoma and adenoid cystic carcinoma. Less common malignancies include rhabdomyosarcoma, adenocarcinoma, and undifferentiated carcinoma.<Reference refidx="1"/><Reference refidx="8"/><Reference refidx="10"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/> Mucoepidermoid carcinoma is usually low or intermediate grade, although high-grade tumors do occur. Recurrent <GeneName>CRTC1</GeneName>::<GeneName>MAML2</GeneName> fusion genes have been detected in pediatric mucoepidermoid carcinomas, reflecting the common chromosome translocation t(11;19)(q21;p13) that is also seen in adults with salivary gland tumors.<Reference refidx="16"/> In one study, 12 of 12 tumors were positive for <GeneName>CRTC1</GeneName>::<GeneName>MAML2</GeneName> fusion transcripts.<Reference refidx="17"/> </Para><Para id="_2428">Mammary analogue secretory carcinoma (MASC) of the salivary gland, also called salivary gland secretory carcinoma,<Reference refidx="18"/> is a newly described pathological entity that has been seen in children.<Reference refidx="19"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>] In one review, it was estimated that 12% of MASC cases occurred in the pediatric population.<Reference refidx="20"/><Reference refidx="21"/> MASC (salivary gland secretory carcinoma) is characterized by an <GeneName>ETV6</GeneName>::<GeneName>NTRK3</GeneName> fusion gene.<Reference refidx="22"/></Para><Para id="_2427">Metachronous mucoepidermoid carcinomas may occur in association with childhood leukemias and lymphomas.<Reference refidx="23"/>  One retrospective study compared 12 pediatric patients with metachronous mucoepidermoid carcinomas secondary to acute lymphoblastic leukemia (ALL) and 6 pediatric and young adult patients with primary mucoepidermoid carcinomas.  <GeneName>KMT2A</GeneName> rearrangements were detected in pediatric metachronous mucoepidermoid carcinomas, and <GeneName>KMT2A</GeneName> rearrangements were detected in the leukemia that preceded the mucoepidermoid carcinoma in 7 of the 12 patients.  The prognosis of patients with concomitant metachronous mucoepidermoid carcinomas and ALL was worse than the prognosis of patients with primary mucoepidermoid carcinomas.</Para></SummarySection><SummarySection id="_1972"><Title>Prognosis</Title><Para id="_1344">The 5-year overall survival (OS) rate for pediatric patients with salivary gland tumors is approximately 95%.<Reference refidx="24"/> A review of the Surveillance, Epidemiology, and End Results (SEER) Program database identified 284 patients younger than 20 years with tumors of the parotid gland.<Reference refidx="25"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>]  The OS rate was 96% at 5 years, 95% at 10 years, and 83% at 20 years. Adolescents had higher mortality rates (7.1%) than children younger than 15 years (1.6%; <Emphasis>P</Emphasis> = .23). </Para><Para id="_2429">In an international systematic review of primary pediatric salivary gland tumors, there were 2,215 patients with malignant tumors between the ages of 0.3 and 19 years (mean age, 13.3 years). The 5-year OS rate was 93.1%, and the local recurrence rate was 18.1%  in patients with malignant neoplasms.<Reference refidx="12"/></Para><Para id="_1973">A retrospective multi-institutional survey identified 103 patients younger than 18 years with parotid gland cancer. Mucoepidermoid carcinoma was the most common histology (71 patients).<Reference refidx="26"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>]  The authors did not report if patients underwent previous therapies. However, they mentioned that 12 of 103 patients had a history of lymphoma.  The 10-year relapse-free survival (RFS) rate for the entire group was 91%. Presence of intraparotid lymph node metastasis (LNM) was associated with significantly worse event-free survival and OS, as was history of previous therapy for lymphoma. The 10-year RFS rate was 91% for patients without intraparotid LNM and 37% for patients with intraparotid LNM.</Para><Para id="_1876">Mucoepidermoid carcinoma is the most common type of treatment-related salivary gland tumor. With standard therapy, the 5-year survival rate is about 95% for patients with this tumor.<Reference refidx="15"/><Reference refidx="27"/><Reference refidx="28"/></Para><Para id="_2424">A retrospective review identified 57 pediatric patients (aged &lt;18 years)  (4.6%) and 1,192 adult patients (95.4%) with acinic cell carcinoma.<Reference refidx="29"/> Clinical LNMs were rare in children (n &lt; 10) and adults (n = 88; 7.4%). Occult LNMs were uncommon in pediatric patients (n &lt; 5) and adult patients (n = 41; 4.6%). The 3-year OS rate was 97.8% for pediatric patients. Adult patients with LNMs had worse 3-year OS rates than those without LNMs (66.0% vs. 96.3%; <Emphasis>P</Emphasis> &lt; .001).</Para><Para id="_2430">A retrospective study used the National Cancer Database to identify 72 patients between the ages of 0 and 21 years with adenoid cystic carcinoma of parotid and submandibular glands. The median age was 18 years, and 72.2% of patients were between the  ages of 16 and 21 years. All patients had primary surgery. Most of the patients underwent lymph node dissection, and 70.8% of patients received radiation therapy. The 5-year OS rate was 93.2%, and the 10-year OS rate was 85.0%.<Reference refidx="30"/></Para></SummarySection><SummarySection id="_939"><Title>Treatment of Childhood Salivary Gland Tumors</Title><Para id="_1974"> The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network - European Registry) has published consensus guidelines for the diagnosis and treatment of childhood salivary gland tumors.<Reference refidx="31"/></Para><Para id="_1884">Treatment options for childhood salivary gland tumors include the following:</Para><OrderedList id="_1885" Style="Arabic"><ListItem><SummaryRef href="CDR0000790384#_1975" url="/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">Surgery</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000790384#_1976" url="/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000790384#_1977" url="/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">Targeted therapy</SummaryRef>.</ListItem></OrderedList><SummarySection id="_1975"><Title>Surgery</Title><Para id="_940">Radical surgical
removal is the treatment of choice for salivary gland tumors whenever possible, with additional use of
radiation therapy for high-grade tumors or tumors that have
invasive characteristics such as LNM, positive surgical margins, extracapsular extension, or perineural extension.<Reference refidx="24"/><Reference refidx="32"/><Reference refidx="33"/>; <Reference refidx="9"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>] Parotid gland tumors are removed with the aid of neurological monitoring to prevent damage to the facial nerve.</Para></SummarySection><SummarySection id="_1976"><Title>Radiation therapy</Title><Para id="_1886">In an international systematic review of 2,215 pediatric patients with malignant salivary tumors, 28.9% received surgery and radiation therapy, 1.8% received surgery, radiation therapy, and chemotherapy, and 0.2% received radiation therapy alone.<Reference refidx="12"/>  One retrospective study compared proton  therapy with conventional radiation therapy and found that proton therapy had a favorable acute toxicity and dosimetric profile.<Reference refidx="34"/> Another retrospective study used brachytherapy with iodine I 125 seeds to treat 24 children with mucoepidermoid carcinoma who had high-risk factors.  Seeds were implanted within 4 weeks of surgical resection.  With a median follow-up of 7.2 years, the disease-free survival and OS rates were 100%. No severe radiation-associated complications were reported.<Reference refidx="35"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>]</Para></SummarySection><SummarySection id="_1977"><Title>Targeted therapy</Title><Para id="_1978">Objective responses have been observed in all reported patients with recurrent <GeneName>NTRK</GeneName> fusion–positive MASC who were treated with entrectinib or larotrectinib.<Reference refidx="36"/><Reference refidx="37"/> Ten of 11 adolescent or adult patients with <GeneName>TRK</GeneName> fusion–positive salivary gland tumors who were treated with larotrectinib experienced partial or complete responses.<Reference refidx="37"/> </Para></SummarySection><Para id="_941">For more information, see <SummaryRef href="CDR0000062920" url="/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq">Salivary Gland
Cancer Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_1808"><Title>Treatment Options Under Clinical Evaluation for Childhood Salivary Gland Tumors</Title><Para id="_1873">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="21928420">Sultan I, Rodriguez-Galindo C, Al-Sharabati S, et al.: Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck 33 (10): 1476-81, 2011.</Citation><Citation idx="2" PMID="25473782">Cesmebasi A, Gabriel A, Niku D, et al.: Pediatric head and neck tumors: an intra-demographic analysis using the SEER* database. Med Sci Monit 20: 2536-42, 2014.</Citation><Citation idx="3" PMID="25572913">Chowdhry AK, McHugh C, Fung C, et al.: Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. Cancer 121 (9): 1436-45, 2015.</Citation><Citation idx="4" PMID="22836059">Boukheris H, Stovall M, Gilbert ES, et al.: Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 85 (3): 776-83, 2013.</Citation><Citation idx="5" PMID="15183580">da Cruz Perez DE, Pires FR, Alves FA, et al.: Salivary gland tumors in children and adolescents: a clinicopathologic and immunohistochemical study of fifty-three cases. Int J Pediatr Otorhinolaryngol 68 (7): 895-902, 2004.</Citation><Citation idx="6" PMID="18809268">Muenscher A, Diegel T, Jaehne M, et al.: Benign and malignant salivary gland diseases in children A retrospective study of 549 cases from the Salivary Gland Registry, Hamburg. Auris Nasus Larynx 36 (3): 326-31, 2009.</Citation><Citation idx="7" PMID="22498386">Fu H, Wang J, Wang L, et al.: Pleomorphic adenoma of the salivary glands in children and adolescents. J Pediatr Surg 47 (4): 715-9, 2012.</Citation><Citation idx="8" PMID="22267165">Galer C, Santillan AA, Chelius D, et al.: Minor salivary gland malignancies in the pediatric population. Head Neck 34 (11): 1648-51, 2012.</Citation><Citation idx="9" PMID="23140879">Thariat J, Vedrine PO, Temam S, et al.: The role of radiation therapy in pediatric mucoepidermoid carcinomas of the salivary glands. J Pediatr 162 (4): 839-43, 2013.</Citation><Citation idx="10" PMID="25132368">Chiaravalli S, Guzzo M, Bisogno G, et al.: Salivary gland carcinomas in children and adolescents: the Italian TREP project experience. Pediatr Blood Cancer 61 (11): 1961-8, 2014.</Citation><Citation idx="11" PMID="18205745">Laikui L, Hongwei L, Hongbing J, et al.: Epithelial salivary gland tumors of children and adolescents in west China population: a clinicopathologic study of 79 cases. J Oral Pathol Med 37 (4): 201-5, 2008.</Citation><Citation idx="12" PMID="33314344">Louredo BVR, Santos-Silva AR, Vargas PA, et al.: Clinicopathological analysis and survival outcomes of primary salivary gland tumors in pediatric patients: A systematic review. J Oral Pathol Med 50 (5): 435-443, 2021.</Citation><Citation idx="13" PMID="16618905">Rahbar R, Grimmer JF, Vargas SO, et al.: Mucoepidermoid carcinoma of the parotid gland in children: A 10-year experience. Arch Otolaryngol Head Neck Surg 132 (4): 375-80, 2006.</Citation><Citation idx="14" PMID="20585877">Kupferman ME, de la Garza GO, Santillan AA, et al.: Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol 17 (12): 3301-7, 2010.</Citation><Citation idx="15" PMID="24419404">Aro K, Leivo I, Mäkitie A: Management of salivary gland malignancies in the pediatric population. Curr Opin Otolaryngol Head Neck Surg 22 (2): 116-20, 2014.</Citation><Citation idx="16" PMID="28139061">Locati LD, Collini P, Imbimbo M, et al.: Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatr Blood Cancer 64 (9): , 2017.</Citation><Citation idx="17" PMID="26221861">Techavichit P, Hicks MJ, López-Terrada DH, et al.: Mucoepidermoid Carcinoma in Children: A Single Institutional Experience. Pediatr Blood Cancer 63 (1): 27-31, 2016.</Citation><Citation idx="18" PMID="37070739">Baněčková M, Thompson LDR, Hyrcza MD, et al.: Salivary Gland Secretory Carcinoma: Clinicopathologic and Genetic Characteristics of 215 Cases and Proposal for a Grading System. Am J Surg Pathol 47 (6): 661-677, 2023.</Citation><Citation idx="19" PMID="34606389">Simon CT, McHugh JB, Rabah R, et al.: Secretory Carcinoma in Children and Young Adults: A Case Series. Pediatr Dev Pathol 25 (2): 155-161, 2022 Mar-Apr.</Citation><Citation idx="20" PMID="28802370">Ngouajio AL, Drejet SM, Phillips DR, et al.: A systematic review including an additional pediatric case report: Pediatric cases of mammary analogue secretory carcinoma. Int J Pediatr Otorhinolaryngol 100: 187-193, 2017.</Citation><Citation idx="21" PMID="28370824">Khalele BA: Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck 39 (6): 1243-1248, 2017.</Citation><Citation idx="22" PMID="20410810">Skálová A, Vanecek T, Sima R, et al.: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34 (5): 599-608, 2010.</Citation><Citation idx="23" PMID="37517063">Othman BK, Steiner P, Leivo I, et al.: Rearrangement of KMT2A Characterizes a Subset of Pediatric Parotid Mucoepidermoid Carcinomas Arising Metachronous to Acute Lymphoblastic Leukemia. Fetal Pediatr Pathol 42 (5): 796-807, 2023.</Citation><Citation idx="24" PMID="21500170">Rutt AL, Hawkshaw MJ, Lurie D, et al.: Salivary gland cancer in patients younger than 30 years. Ear Nose Throat J 90 (4): 174-84, 2011.</Citation><Citation idx="25" PMID="24036747">Allan BJ, Tashiro J, Diaz S, et al.: Malignant tumors of the parotid gland in children: incidence and outcomes. J Craniofac Surg 24 (5): 1660-4, 2013.</Citation><Citation idx="26" PMID="32045566">Seng D, Fang Q, Liu F, et al.: Intraparotid Lymph Node Metastasis Decreases Survival in Pediatric Patients With Parotid Cancer. J Oral Maxillofac Surg 78 (5): 852.e1-852.e6, 2020.</Citation><Citation idx="27" PMID="21280198">Verma J, Teh BS, Paulino AC: Characteristics and outcome of radiation and chemotherapy-related mucoepidermoid carcinoma of the salivary glands. Pediatr Blood Cancer 57 (7): 1137-41, 2011.</Citation><Citation idx="28" PMID="16783829">Védrine PO, Coffinet L, Temam S, et al.: Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms. Head Neck 28 (9): 827-33, 2006.</Citation><Citation idx="29" PMID="35259039">Dublin JC, Oliver JR, Tam MM, et al.: Nodal Metastases in Pediatric and Adult Acinic Cell Carcinoma of the Major Salivary Glands. Otolaryngol Head Neck Surg 167 (6): 941-951, 2022.</Citation><Citation idx="30" PMID="38418934">Phillips AL, Li C, Liang J, et al.: Adenoid cystic carcinoma of the parotid and submandibular glands in children and young adults: A population-based study. Pediatr Blood Cancer 71 (5): e30928, 2024.</Citation><Citation idx="31" PMID="34174160">Surun A, Schneider DT, Ferrari A, et al.: Salivary gland carcinoma in children and adolescents: The EXPeRT/PARTNER diagnosis and treatment recommendations. Pediatr Blood Cancer 68 (Suppl 4): e29058, 2021.</Citation><Citation idx="32" PMID="21284057">Ryan JT, El-Naggar AK, Huh W, et al.: Primacy of surgery in the management of mucoepidermoid carcinoma in children. Head Neck 33 (12): 1769-73, 2011.</Citation><Citation idx="33" PMID="29688836">Morse E, Fujiwara RJT, Husain Z, et al.: Pediatric Salivary Cancer: Epidemiology, Treatment Trends, and Association of Treatment Modality with Survival. Otolaryngol Head Neck Surg 159 (3): 553-563, 2018.</Citation><Citation idx="34" PMID="26232128">Grant SR, Grosshans DR, Bilton SD, et al.: Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics. Radiother Oncol 116 (2): 309-15, 2015.</Citation><Citation idx="35" PMID="27576792">Mao MH, Zheng L, Wang XM, et al.: Surgery combined with postoperative (125) I seed brachytherapy for the treatment of mucoepidermoid carcinoma of the parotid gland in pediatric patients. Pediatr Blood Cancer 64 (1): 57-63, 2017.</Citation><Citation idx="36" PMID="28183697">Drilon A, Siena S, Ou SI, et al.: Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7 (4): 400-409, 2017.</Citation><Citation idx="37" PMID="29466156">Drilon A, Laetsch TW, Kummar S, et al.: Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378 (8): 731-739, 2018.</Citation></ReferenceSection></SummarySection><SummarySection id="_942"><Title>Sialoblastoma</Title><Para id="_943">Sialoblastoma is usually a benign tumor presenting in the neonatal period, but it has been reported to present as late as age 15 years. Sialoblastoma rarely metastasizes to the lungs, lymph nodes, or bones.<Reference refidx="1"/></Para><Para id="_1887">The main treatment for patients with sialoblastoma is surgical resection. However, it has been suggested that neoadjuvant chemotherapy may be indicated as an alternative to mutilating surgery. Chemotherapy regimens with carboplatin, epirubicin, vincristine, etoposide, dactinomycin, doxorubicin, and ifosfamide have produced responses in two children with sialoblastoma.<Reference refidx="2"/>; <Reference refidx="3"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] </Para><ReferenceSection><Citation idx="1" PMID="27368441">Irace AL, Adil EA, Archer NM, et al.: Pediatric sialoblastoma: Evaluation and management. Int J Pediatr Otorhinolaryngol 87: 44-9, 2016.</Citation><Citation idx="2" PMID="20554035">Prigent M, Teissier N, Peuchmaur M, et al.: Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery. Int J Pediatr Otorhinolaryngol 74 (8): 942-5, 2010.</Citation><Citation idx="3" PMID="16514617">Scott JX, Krishnan S, Bourne AJ, et al.: Treatment of metastatic sialoblastoma with chemotherapy and surgery. Pediatr Blood Cancer 50 (1): 134-7, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_1864"><SectMetaData><SectionType>Unusual Cancers Special Considerations</SectionType></SectMetaData><Title>Special Considerations for the Treatment of Children With Cancer</Title>

<Para id="_1864_md_3">Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.<Reference refidx="1"/>    Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills
of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation
to achieve optimal survival and quality of life:</Para>
        <ItemizedList id="_1864_md_4" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Pathologists.</ListItem><ListItem>Pediatric radiation
oncologists.</ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Ophthalmologists.</ListItem><ListItem> Rehabilitation
specialists.</ListItem><ListItem>Pediatric oncology nurses.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child-life professionals.</ListItem><ListItem>Psychologists.</ListItem><ListItem>Nutritionists.</ListItem></ItemizedList>
 <Para id="_1864_md_5">For specific information about supportive care for children and adolescents with cancer, see the summaries on <ExternalRef xref="https://www.cancer.gov/publications/pdq/information-summaries/supportive-care">Supportive and Palliative Care</ExternalRef>.</Para><Para id="_1864_md_6">The American Academy of Pediatrics has outlined guidelines for
pediatric cancer centers and their role in the treatment of children and adolescents
with cancer.<Reference refidx="2"/>  At
these centers, clinical trials are available for most  types of cancer that occur in children and adolescents, and the opportunity
to participate is offered to most patients and their families.  Clinical
trials for children and adolescents diagnosed with cancer are generally
designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis.  Most of the progress in identifying curative
therapies for childhood cancers has been achieved through clinical trials. 
Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_1864_md_7">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.  For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>.</Para>
<Para id="_1864_md_8">Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.<Reference refidx="6"/> The U.S. <ExternalRef xref="https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf">Rare Diseases Act of 2002</ExternalRef> defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.</Para><Para id="_1864_md_9">The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.<Reference refidx="7"/><Reference refidx="8"/> In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:</Para><ItemizedList id="_1864_md_10" Style="bullet"><ListItem>A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included  in the very rare group due to a lack of knowledge and expertise in the management of these tumors.<Reference refidx="9"/></ListItem><ListItem>The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).<Reference refidx="10"/>  These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.<Reference refidx="4"/><Para id="_11"> Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.</Para></ListItem></ItemizedList><Para id="_1864_md_12">These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.</Para><Para id="_1837">Information about these tumors may also be found in sources relevant to
adults with cancer, such as <SummaryRef href="CDR0000062920" url="/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq">Salivary Gland Cancer Treatment</SummaryRef>.</Para><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2">American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics  134 (2): 410-4, 2014. <ExternalRef xref="https://pediatrics.aappublications.org/content/134/2/410">Also available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="5">Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. 	Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statistics-network/explorer/">Available online</ExternalRef>. Last accessed December 30, 2024.</Citation><Citation idx="6" PMID="24488779">Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr.</Citation><Citation idx="7" PMID="28687376">Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017.</Citation><Citation idx="8" PMID="28542893">DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017.</Citation><Citation idx="9" PMID="30785015">Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019.</Citation><Citation idx="10" PMID="20956621">Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_1833"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (08/23/2024)</Title><Para id="_1834">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_2426">This summary was comprehensively reviewed.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000790384#_AboutThis_1" url="/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood salivary gland tumors. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Salivary Gland Tumors Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Denise Adams, MD (Children's Hospital Boston)</ListItem><ListItem>Karen J. Marcus, MD, FACR (Dana-Farber of Boston Children's Cancer Center and Blood Disorders Harvard Medical School)</ListItem><ListItem>William H. Meyer, MD</ListItem><ListItem>Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)</ListItem><ListItem>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>Alberto S. Pappo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>D. Williams Parsons, MD, PhD (Texas Children's Hospital)</ListItem><ListItem>Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)</ListItem><ListItem>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>Stephen J. Shochat, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Salivary Gland Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/head-and-neck/hp/child/salivary-gland-treatment-pdq">https://www.cancer.gov/types/head-and-neck/hp/child/salivary-gland-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 29337478]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2018-01-08</DateFirstPublished><DateLastModified>2024-08-23</DateLastModified></Summary>
